Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer

Journal of Experimental & Clinical Cancer Research

Shu L Zhang¹  Yao H Ji²  Wei G Jiang³  Ning Wang¹  Shi Z Wang¹  Yao Zhang¹  Qiao Zhang¹ 

[1] Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang(110004), China;Virus Laboratory, Shengjing Hospital of China Medical University, Shenyang (110004), China;Department of Pathology, Shengjing Hospital of China Medical University, Shenyang (110004), China

关键词: angiogenesis;    apoptosis;    immunohistochemical study;    Tissue factor pathway inhibitor-2;    cervical cancer;   

Others  :  826943
DOI  :  10.1186/1756-9966-31-1

 received in 2011-09-30, accepted in 2012-01-02,  发布年份 2012

【 摘 要 】

Background

Tissue factor pathway inhibitor-2 (TFPI-2) is an extracellular matrix associated broad-spectrum Kunitz-type serine proteinase inhibitor. Recently, down regulation of TFPI-2 was suggested to be involved in tumor invasion and metastasis in some cancers.

Methods

This study involved 12 normal cervical squamous epithelia, 48 cervical intraepithelial neoplasia (CIN), and 68 cervical cancer. The expression of TFPI-2, Ki-67 and vascular endothelial growth factor (VEGF) were investigated by immunohistochemistry staining. The apoptolic index(AI) was determined with an in situ end-labeling assay(TUNEL). And the marker of CD34 staining was used as an indicator of microvessel density (MVD).

Results

TFPI-2 expression has a decreasing trend with the progression of cervical cancer and was significantly correlated with FIGO stage, lymph node metastasis and HPV infection. In addition, there were significant positive correlations between the grading of TFPI-2 expression and AI(P = 0.004). In contrast, the expression of TFPI-2 and VEGF or MVD was negatively correlated (both p < 0.001). However, we did not establish any significant correlation between Ki-67 and TFPI-2 expression in cervical cancer.

Conclusions

The results suggested that the expression of TFPI-2 had a decreasing trend with tumor progression of cervical cancer. There was a close association between the expression of TFPI-2 and tumor cell apoptosis and angiogenesis in patients with cervical cancer. TFPI-2 may play an inhibitive role during the development of cervical cancer.

【 授权许可】

   
2012 Zhang et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Waggoner SE: Cervical cancer. Lancet 2003, 361:2217-2225.
• [2]Moscicki AB, Schiffman M, Kjaer S, Villa LL: Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine 2006, 24(suppl 3):S42-51.
• [3]Udagawa K, Yasumitsu H, Esaki M, Sawada H, Nagashima Y, Aoki I, Jin M, Miyagi E, Nakazawa T, Hirahara F, Miyazaki K, Miyagi Y: Subcellularlocalization of PP5/TFPI-2 in human placenta: a possible role of PP5/TFPI-2 as an anti-coagulantonthe surface of syncytiotrophoblasts. Placenta 2002, 23:145-153.
• [4]Herman MP, Sukhova GK, Kisiel W, Foster D, Kehry MR, Libby P, Schönbeck U: Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001, 107:1117-1126.
• [5]Sugiyama T, Ishii S, Yamamoto J, Irie R, Saito K, Otuki T, Wakamatsu A, Suzuki Y, Hio Y, Ota T, Nishikawa T, Sugano S, Masuho Y, Isogai T: cDNA macroarray analysis of gene expression in synoviocytes stimulated with TNF alpha. FEBS Lett 2002, 517:121-128.
• [6]Rao CN, Cook B, LiuY Chilukuri K, Stack MS, Foster DC, Kisiel W, Woodley DT: HT-1080 fibrosarcoma cellmatrix degradationand invasion are inhibited by thematrix-associated serineprotease inhibitor TFPI-2/33 kDaMSPI. Int JCancer 1998, 76:749-756.
• [7]Chand HS, Schmidt AE, Bajaj SP, Kisiel W: Structure function analysis of the reactive site in the first Kunitz type domain of human tissue factor pathway inhibitor-2. J Biol Chem 2004, 279:17500-17507.
• [8]Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, Spandidos DA, Mazzarino C: Uterine cervical carcinoma: role of matrix metalloproteinases. International Journal of Oncology 2009, 34:897-904.
• [9]Hitendra ChandS, Donald FosterC, Walter Kisiel: Structure, function andbiology of tissue factor pathway inhibitor-2. ThrombHaemost 2005, 94:1122-1130.
• [10]Shumin Wang, Xue Xiao, Xiaoying Zhou, Tingting Huang, Chunping Du, Nana Yu, Yingxi Mo, Longde Lin, Jinyan Zhang, Ning Ma, Mariko Murata, Guangwu Huang, Zhe Zhang: TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010, 10:617. BioMed Central Full Text
• [11]Wong CM, Ng YL, Lee JM, Wong CC, Cheung OF, Chan CY, Tung EK, Ching YP, Ng IO: Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007, 45:1129-1138.
• [12]Ran Y, Pan J, Hu H, Zhou Z, Sun L, Peng L, Yu L, Sun L, Liu J, Yang Z: A novel role for tissue factor pathway inhibitor-2 in the therapy of human esophageal carcinoma. Hum Gene Ther 2009, 20:41-49.
• [13]Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A, Kiviat N: Discovery of Novel Methylation Biomarers in Cervical Carcinoma by Global Demethylation and Microarray Analysis. Cancer Epidemiol Biomarkers Prev 2006, 15:114-123.
• [14]Santin AD, Zhan F, Bignotti E, Siegel ER, Cané S, Bellone S, Palmieri M, Anfossi S, Thomas M, Burnett A, Kay HH, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J Jr, Pecorelli S: Gene expression profiles of primary HPV16-and HPV18-infected early stage cervical cancers and normal cervical epithetlium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 2005, 331:269-291.
• [15]Iino M, Foster DC, Kisiel W: Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler Thromb Vasc Biol 1998, 18:40-46.
• [16]Hubé F, Reverdiau P, Iochmann S, Rollin J, Cherpi-Antar C, Gruel Y: Transcriptional Silencing of the TFPI-2 Gene by Promoter Hypermethylation in Choriocarcinoma Cells. Biol Chem 2003, 384:1029-1034.
• [17]Gessler F, Voss V, Seifert V, Gerlach R, Kögel D: Knockdown of TFPI-2 promotes migration and invasion of glioma cells. Neurosci Lett 2011, 497:49-54.
• [18]Konduri SD, Tasiou A, Chandrasekar N, Rao JS: Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol 2001, 18:127-131.
• [19]Tang Z, Geng G, Huang Q, Xu G, Hu H, Chen J, Li J: Expression of tissue factor pathway inhibitor 2 in human pancreatic carcinoma and its effect on tumor growth, invasion, and migration in vitro and in vivo. J Surg Res 2011, 167:62-69.
• [20]Iochmann S, Bléchet C, Chabot V, Saulnier A, Amini A, Gaud G, Gruel Y, Reverdiau P: Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion. Clin Exp Metastasis 2009, 26:457-467.
• [21]Wojtukiewicz MZ, Sierko E, Zimnoch L, Kozlowski L, Kisiel W: Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost 2003, 90:140-146.
• [22]Rollin J, Iochmann S, Blechet C, Hube F, Regina S, Guyetant S, Lemarie E, Reverdiau P, Gruel Y: Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. British Journal of Cancer 2005, 92:775-783.
• [23]Hongshen Guo, Yifeng Lin, Hongwei Zhang, Juan Liu, Nong Zhang, Yiming Li, Desheng Kong, Qiqun Tang, Duan Ma: Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Molecular Biology 2007, 8:110. BioMed Central Full Text
• [24]Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM, ALTS Group: A 2-year prospective study of human papilloma virus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007, 195:1582-1589.
• [25]Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ: HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006, 208:152-164.
• [26]Shoji Y, Saegusa M, Takano Y, Ohbu M, Okayasu I: Correlation of apoptosis with tumour cell differentiation, progression, and HPV infection in cervical carcinoma. J Clin Pathol 1996, 49:134-138.
• [27]Joseph George, Christopher GondiS, Dzung DinhH, Meena Gujrati, Jasti RaoS: Restoration of TFPI-2 in a Human Glioblastoma Cell Line Triggers Caspase Mediated Pathway and Apoptosis. Clin Cancer Res 2007, 13:3507-3517.
• [28]Kempaiah P, Kisiel W: Human tissue factor pathway inhibitor-2 induces caspase-mediated apoptosis in a human fibrosarcoma cell line. Apoptosis 2008, 13:702-715.
• [29]Shih SC, Robinson GS, Perruzzi CA, Calvo A, Desai K, Green JE, Ali IU, Smith LE, Senger DR: Molecular profiling of angiogenesis markers. Am J Pathol 2002, 161:35-41.
• [30]Chand HS, Du X, Ma D, Inzunza HD, Kamei S, Foster D, Brodie S, Kisiel W: The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice. Blood 2004, 103:1069-1077.
• [31]Yanamandra N, Kondraganti S, Gondi CS, Gujrati M, Olivero WC, Dinh DH, Rao JS: Recombinant adenoassocia- ted virus (rAAV) exp ressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer 2005, 115:998-1005.
• [32]Zhenhua Xu, Debasish Maiti, Walter Kisiel, Elia DuhJ: Endothelial Cells Growth Factor and Suppresses Growth Factor-Induced Proliferation of Tissue Factor Pathway Inhibitor-2 Is Upregulated by Vascular Endothelial. Arterioscler Thromb Vasc Biol 2006, 26:2819-2825.